Drug Profile

MT 304

Alternative Names: MT-304

Latest Information Update: 31 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Myeloid Therapeutics
Developer CREATE Medicines
Class Antineoplastics; CAR-NK cell therapies; CAR-T cell therapies; Gene therapies
Mechanism of Action Immunologic cytotoxicity; Myeloid cell replacements; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

06 Oct 2025 Myeloid Therapeutics is now called CREATE Medicines
06 Oct 2025 Preclinical trials in HER2-positive-breast-cancer in USA (Parenteral)
06 Oct 2025 CREATE Medicines plans a phase I/II basket trial for Solid tumours in fourth quarter of 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com